Nuvation Bio Reveals IBTROZI Showed Highly Durable Responses in Longer-Term Follow-Up Data From Pivotal Studies Presented At AACR 2026; IBTROZI Also Demonstrated A High Overall Response Rate In TKI-Naïve Patients At 89.8%; Preclinical Data Presented At AACR Showed Taletrectinib's Potential For Suppressing TrkB-mediated Lung Cancer Cell Migration

Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced results from a pooled analysis of long-term follow-up data from the pivotal TRUST-I and TRUST-II trials for IBTROZI® (taletrectinib) in patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The updated efficacy and safety results for both TKI-naïve and TKI-pretreated patients were presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 in oral and poster presentations. The long-term pooled results in TKI-naïve patients demonstrated a confirmed objective response rate (cORR) of 89.8%, a median duration of response (mDOR) of 49.7 months and a median progression-free survival (mPFS) of 46.1 months. Updated results from the TRUST-I study were also simultaneously published in the Journal of Clinical Oncology, demonstrating robust ORR, mDOR and mPFS in TKI-naïve patients, with a median follow up of 51 months.